BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
Bio-Path Holdings, Inc. (the Company) held its 2016 annual
meeting (the 2016 Annual Meeting) of stockholders of the Company
on December 15, 2016 in The Woodlands, Texas. At the 2016 Annual
Meeting, the Companys stockholders: (i) elected each of the five
persons listed below under Proposal 1 to serve as a director of
the Company until its 2017 annual meeting of stockholders; (ii)
approved, on a non-binding advisory basis, the compensation of
the Companys named executive officers; and (iii) ratified and
approved the appointment of BDO USA, LLP as the Companys
registered independent public accounting firm for the Companys
fiscal year ending December 31, 2016. The following describes the
results of the voting at the 2016 Annual Meeting:
| Proposal 1: |
The election of directors to serve until the 2017 annual meeting of stockholders of the Company: |
| Name of Nominee | Shares Voted For | Shares Voted Against | Shares Withheld | Shares Abstained | Broker Non-Votes |
| Peter H. Nielsen | 29,014,240 | — | 819,909 | — | 49,332,267 |
| Michael J. Garrison | 29,323,526 | — | 510,623 | — | 49,332,267 |
| Heath W. Cleaver | 29,363,000 | — | 471,149 | — | 49,332,267 |
| Amy P. Sing, M.D. | 29,320,399 | — | 513,750 | — | 49,332,267 |
| Douglas P. Morris | 29,327,819 | — | 506,330 | — | 49,332,267 |
| Proposal 2: |
Advisory (non-binding) vote approving the compensation of the Companys named executive officers: |
| Shares Voted For | Shares Voted Against | Shares Withheld | Shares Abstained | Broker Non-Votes |
| 27,802,666 | 1,938,088 | — | 93,395 | 49,332,267 |
| Proposal 3: |
Ratification and approval of the appointment of BDO USA, LLP as the Companys registered independent public accounting firm for its fiscal year ending December 31, 2016: |
| Shares Voted For | Shares Voted Against | Shares Withheld | Shares Abstained | Broker Non-Votes |
| 78,133,722 | 326,443 | — | 706,251 | — |
| Item 7.01 | Regulation FD Disclosure. |
At the 2016 Annual Meeting, Peter H. Nielsen, President and Chief
Executive Officer of the Company, presented highlights of the
Company during 2016. A copy of the slide presentation used for
Mr. Nielsens presentation is attached hereto as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit Number | Description |
| 99.1 | Slide Presentation dated December 2016 |
About BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH)
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer. BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Recent Trading Information
BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) closed its last trading session up +0.08 at 1.28 with 159,884 shares trading hands.
